[Form 4/A] Tecogen Inc. Amended Insider Trading Activity

Rhea-AI Filing Summary

Form 4 for HeartSciences Inc. (HSCS) discloses a new equity award to director Bruce Bent. On 07/09/2025 he received 25,000 non-derivative stock options under the 2023 Equity Incentive Plan at an exercise price of $4.37 per share, expiring on 07/09/2035. Vesting terms: 25 % vested immediately and the remaining 75 % will vest in equal quarterly tranches over the next nine months, subject to continued board service. The grant is compensation-related; no open-market purchase or sale of common shares occurred, so cash flow and immediate dilution effects are minimal. Following the grant, Bent directly holds the 25,000 options; no indirect ownership is reported.

Insights

Securities Analyst

TL;DR: Routine director option grant; aligns incentives, negligible dilution, neutral to share price.

The filing reflects standard board compensation rather than an opportunistic trade. A 25,000-unit grant is small relative to typical micro-cap floats and carries a 10-year term at a strike set above current price (not provided here), so the award is only valuable if the company appreciates. Immediate vesting of 6,250 options boosts alignment, while staggered quarterly vesting supports director retention. No change to insider share count or cash proceeds until exercise, so fundamental valuation and liquidity are unaffected at this stage. Overall market impact is neutral; investors may view ongoing equity-based pay as ordinary course.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PANORA ROBERT A

(Last) (First) (Middle)

C/O TECOGEN, INC.

76 TREBLE COVE ROAD, BLDG 1

(Street)

N. BILLERICA MA 01862

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TECOGEN INC. [ TGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO and President

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
06/20/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/03/2025		S(1)		26,000	D	$4.69	44,000	D
Common Stock	06/04/2025		S(1)		31,000	D	$5	13,000	D
Common Stock	06/16/2025		M(2)		12,723	A	$0.786	25,723	D
Common Stock	06/16/2025		M(2)		30,000	A	$0.71	55,723	D
Common Stock	06/16/2025		M(2)		52,500	A	$1.1	108,223	D
Common Stock	06/18/2025		S(1)		13,000	D	$5.03	95,223	D
Common Stock	06/23/2025		S(1)		31,800	D	$6.36	63,423	D
Common Stock	06/24/2025		S(1)		900	D	$6.86	62,523	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.786	06/16/2025		M(2)			12,723	05/12/2016	05/12/2026	Common Stock	12,723	$0.786	0	D
Stock Option (Right to Buy)	$0.71	06/16/2025		M(2)			30,000	(3)	07/09/2030	Common Stock	30,000	$0.71	100,000	D
Stock Option (Right to Buy)	$1.1	06/16/2025		M(2)			52,500	01/21/2023	01/21/2032	Common Stock	52,500	$1.1	0	D

Explanation of Responses:

1. Share sales effected to cover tax liabilities and other obligations. The June 2025 share sales were reported to the company on July 11, 2025.

2. Transaction code corrected

3. 100,000 shares of the 200,000 option shares granted pursuant to Stock Option Agreement dated 7/9/2020 vested on 6/30/2022 upon achievement of Adjusted EBITDA performance milestone.

Remarks:

	/s/ Robert A. Panora	07/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.